About Cosmos Health Inc
- Industry: Health Care
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: GR
- Website: https://www.cosmosholdingsinc.com/
Frequently Asked Questions
What is the 52-week range for COSM?
The 52-week high is $1.32 and the 52-week low is $0.1616.
What is the P/E ratio for COSM?
The P/E ratio data is currently unavailable.
What is the dividend yield for COSM?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -118.89%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -33.08%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.01.
Analyst Recommendation Trends
Wall Street analyst consensus for COSM over the last few months:
Latest COSM News
Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion
The portfolio comprises more than 15 proprietary brands and product lines and 10 branded generics across five product categories, sold in more than 40 countries through pharmacies, hospitals, retail chains and e-commerce. It is manufactured at GMP-certified facilities in Europe and the United States and supported by the Company's services in contract manufacturing, pharmaceutical distribution, telehealth and research and development.
COSM Continues to Grow Business
By Brad Sorensen, CFA NASDAQ: COSM READ THE FULL COSM RESEARCH REPORT Cosmos Health (NASDAQ: COSM) has spent the past several years building what management describes as a vertically integrated healthcare platform spanning pharmaceutical manufacturing, distribution, proprietary brands, nutraceuticals, R&D, and telehealth. Two announcements released on September 28 and September 29 provide
Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue
* Record Q2 2026 revenue of over $15 million, an annualized run-rate of over $60 million, at wholly owned subsidiary CosmoFarm * Revenue up 4.3x under Cosmos Health ownership \- from ~$14 million in fiscal 2017, the last full year before acquisition, to an annualized run-rate of over $60 million; ~330% growth at a CAGR of approximately 18% * Successive record revenue years in 2023, 2024 and 2025, with 2026 expected to continue the trend, based on distribution volumes and performance to date * Ph
Cosmos Health’s CosmoFarm Reports Q2 Revenue Of Over $15M, $60M Annualized Run Rate; Says Robotics, Automation And AI-Enabled Systems Across Procurement, Inventory And Order Execution, With Capacity That Could Support A Further $40M Or More In Annual Revenue, Which Would Provide Infrastructure For Annualized Revenue Above $100M
Record Q2 2026 revenue of over $15 million, an annualized run-rate of over $60 million, at wholly owned subsidiary CosmoFarmRevenue up 4.3x under Cosmos Health ownership - from ~$14 million in fiscal 2017, the last full
Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline
* Contract manufacturing pipeline surpasses $20 million in implied revenue at wholly owned subsidiary Cana Laboratories, representing over $18 million in implied gross profit across the life of agreements * Gross margins of over 90% \- among the highest-margin revenue streams in the Company, with raw materials largely supplied by clients * Record production pipeline of more than 32.7 million units, up approximately sixfold since mid-2024 and close to threefold since the start of this year, with
Cosmos Health's Cana Laboratories Subsidiary Achieves Over $20M In Revenue
Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that the contract manufacturing ("CMO") pipeline
Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June
7 million contracted units added in under two weeks \- Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today * Secured orders for 1.
Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market
* Prime Ledger engaged to structure an asset-specific, non-dilutive tokenized financing for CCX0722 - backed by intellectual property, with no issuance of Cosmos Health common stock * Positions Cosmos Health among the earliest NASDAQ-listed healthcare companies pursuing tokenized IP-backed assets. * CCX0722 is an ingestible, hydrogel-based medical device in development for weight management, using a mechanical mechanism with no systemic absorption * Intellectual property owned outright, with pat
Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units
* 500,000 contracted units of ROSARTIA annually / 2.5 million over five years through a new long-term agreement at wholly owned subsidiary Cana Laboratories * Expands Cosmos Health's manufacturing presence in cardiovascular pharmaceuticals, adding production of statin-based lipid-lowering therapies to Cana's growing contract manufacturing portfolio * Cumulative contract manufacturing orderbook increases to more than 27.
COSM Again Expands its Market and Accelerates its Growth
By Brad Sorensen, CFA NASDAQ: COSM READ THE FULL COSM RESEARCH REPORT We view Cosmos Health’s (NASDAQ: COSM) latest launch of C-ScrubVet as an intriguing extension of the company’s strategy of using its existing manufacturing, regulatory, distribution, and brand infrastructure to enter additional healthcare markets without having to build an entirely new business from scratch. The veterinary
Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market
2 million in adjusted EBITDA and $31 million in net incomeCHICAGO, IL / ACCESS Newswire / September 9, 2026 / ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has received its first orders for its veterinary antimicrobial line, which will be marketed under the brand name C-ScrubVet.C-ScrubVet Wash 4% CHDG is a veterinary antimicrobial cleanser containing 4% chlorhexidine digluconate, effective against bacteria
Related Stocks (Peers)
Companies operating in similar sectors to COSM:
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-30 | Siokas Grigorios | +349,825 | $0.2001 | $70,000 |
| 2026-07-29 | Terzis Georgios | +328,407 | $0.1827 | $60,000 |
| 2026-07-29 | Siokas Grigorios | +766,284 | $0.1827 | $140,000 |
| 2026-06-16 | Terzis Georgios | +168,135 | $0.2498 | $42,000 |
| 2026-06-11 | Siokas Grigorios | +218,447 | $0.206 | $45,000 |
| 2026-06-10 | Siokas Grigorios | +701,447 | $0.2281 | $160,000 |
| 2026-05-19 | Karkantzos Theodoros Christos | -35,000 | - | - |
| 2026-05-19 | Karkantzos Theodoros Christos | +20,000 | $0.283 | $5,660 |
| 2026-05-19 | Hoidas John James | -20,000 | - | - |
| 2026-05-19 | Hoidas John James | +20,000 | $0.283 | $5,660 |
| 2026-05-19 | Demetriades Demetrios G. | -20,000 | - | - |
| 2026-05-19 | Demetriades Demetrios G. | +20,000 | $0.283 | $5,660 |
| 2026-05-19 | Aslidis Anastasios | -40,000 | - | - |
| 2026-05-19 | Aslidis Anastasios | +40,000 | $0.283 | $11,320 |
| 2026-05-19 | Bhutawala Suhel | -20,000 | - | - |
| 2026-05-19 | Bhutawala Suhel | +20,000 | $0.283 | $5,660 |
| 2026-05-19 | Terzis Georgios | -850,000 | - | - |
| 2026-05-19 | Terzis Georgios | +850,000 | $0.283 | $240,550 |
| 2026-05-19 | Siokas Grigorios | -2,350,000 | - | - |
| 2026-05-19 | Siokas Grigorios | +2,350,000 | $0.283 | $665,050 |
| 2026-02-12 | Siokas Grigorios | +388,532 | $0.3732 | $145,000 |
| 2026-02-11 | Siokas Grigorios | +291,262 | $0.412 | $120,000 |
| 2026-01-23 | Siokas Grigorios | +90,325 | $0.4982 | $45,000 |
| 2026-01-20 | Siokas Grigorios | +353,321 | $0.4953 | $175,000 |
| 2026-01-14 | Siokas Grigorios | +493,495 | $0.4458 | $220,000 |
| 2026-01-12 | Siokas Grigorios | +113,185 | $0.5036 | $57,000 |
| 2026-01-08 | Siokas Grigorios | +156,190 | $0.5186 | $81,000 |
| 2026-01-07 | Siokas Grigorios | +124,880 | $0.5205 | $65,000 |
| 2026-01-06 | Siokas Grigorios | +133,953 | $0.5375 | $72,000 |
| 2025-12-31 | Siokas Grigorios | +100,000 | $0.001 | $100 |
| 2025-12-31 | Siokas Grigorios | +1,350,000 | $0.001 | $1,350 |
| 2025-12-31 | Terzis Georgios | +490,000 | $0.001 | $490 |
| 2025-12-31 | Aslidis Anastasios | +20,000 | $0.001 | $20 |
| 2025-12-31 | Hoidas John James | +15,000 | $0.001 | $15 |
| 2025-12-31 | Karkantzos Theodoros Christos | +15,000 | $0.001 | $15 |
| 2025-12-31 | Demetriades Demetrios G. | +15,000 | $0.001 | $15 |
| 2025-12-31 | Bhutawala Suhel | +15,000 | $0.001 | $15 |
| 2025-12-19 | Siokas Grigorios | +88,314 | $0.4869 | $43,000 |
| 2025-12-15 | Siokas Grigorios | +168,472 | $0.4155 | $70,000 |
| 2025-11-28 | Siokas Grigorios | +76,360 | $0.6417 | $49,000 |
| 2025-11-25 | Siokas Grigorios | +55,732 | $0.628 | $35,000 |
| 2025-11-21 | Siokas Grigorios | +56,080 | $0.6776 | $38,000 |
| 2025-11-20 | Siokas Grigorios | +51,315 | $0.6236 | $32,000 |
| 2025-11-19 | Siokas Grigorios | +61,614 | $0.6492 | $40,000 |